Acadian Asset Management
ATOS icon

Acadian Asset Management’s Atossa Therapeutics ATOS Stock Holding History

Acadian Asset Management’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,294
Closed -$46K – 2020
2025
Q4 		$46K Sell
5,294
-1,192
-18% -$15.1K ﹤0.01% 1804
2025
Q3 		$82K Buy
+6,486
New +$80.1K ﹤0.01% 1560
2024
Q4 		– Sell
-972
Closed -$22K – 1639
2024
Q3 		$22K Buy
+972
New +$19.6K ﹤0.01% 1963

Other funds holding ATOS

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Acadian Asset Management's ATOS Position: Q1 2026 in Review

Acadian Asset Management sold out of Atossa Therapeutics (ATOS) in Q1 2026, closing a stake of 5,294 shares — an estimated $46K sold.

Acadian Asset Management first reported a position in ATOS in Q3 2024 and held it in 3 quarters. The position peaked at $82K in Q3 2025. 33 funds tracked by Wall St. Rank hold ATOS as of Q1 2026.

  • Acadian Asset Management reported no remaining Atossa Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Acadian Asset Management sold 5,294 Atossa Therapeutics shares in Q1 2026, an estimated $46K.
  • Acadian Asset Management first reported a position in Atossa Therapeutics in Q3 2024 and held it in 3 quarters.
  • Acadian Asset Management's Atossa Therapeutics position peaked at $82K in Q3 2025.
  • 33 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.